US BioTek Laboratories, a leading provider of diagnostic testing products and services based in the United States, has completed its acquisition of NutriPATH, an Australian clinical pathology laboratory specializing in functional diagnostic testing. The deal was announced on March 10, 2026.
| Acquirer: | US BioTek Laboratories (US) | |
| Target: | NutriPATH (AU) | |
| Deal value: | Undisclosed | |
| Type of deal: | Acquisition | |
| Closing date: | March 9, 2026 | |
| Announcement date: | March 10, 2026 | |
| Buy-side advisors: | Not disclosed | |
| Sell-side advisors: | Not disclosed | |
| Legal buy-side: | Not disclosed | |
| Legal sell-side: | Not disclosed | |
Deal Mechanics
The transaction was completed without the disclosure of specific financial terms, including the deal value. No key terms were made public regarding the acquisition.
Strategic Rationale
US BioTek Laboratories' rationale for acquiring NutriPATH is to expand its global footprint and enhance capabilities in functional diagnostic testing, a growing segment within healthcare diagnostics. The addition of NutriPATH's extensive test menu and clinical expertise will allow US BioTek to offer an expanded range of services to patients and healthcare providers.
Financial Context
The acquisition is part of US BioTek Laboratories' strategic plan to grow its presence in international markets, particularly in the Asia-Pacific region. NutriPATH's operational excellence and market reputation for high-quality testing will complement US BioTek's existing diagnostic solutions.
Outlook
With this deal, US BioTek Laboratories aims to solidify its position as a leader in functional diagnostics on an international scale. The integration of NutriPATH is expected to drive innovation and growth for both companies moving forward.